Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has issued an announcement.
Thiogenesis Therapeutics Corp has announced the extension of its investor relations agreement with Triomphe Holdings Ltd., operating as Capital Analytica, for an additional three months ending December 31, 2025. This extension, which involves a monthly payment of $5,000 to the consultant, aims to enhance the company’s investor relations through social media consultation and engagement services. The extension is subject to acceptance by the TSX Venture Exchange, and no securities are being issued as part of this agreement.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, California. It is publicly traded on the TSX Venture Exchange and the OTCQX in the U.S. The company focuses on developing sulfur-containing prodrugs that serve as precursors to thiol-active compounds, targeting serious pediatric diseases with unmet medical needs. Its lead product candidate, TTI-0102, is undergoing a Phase 2 clinical trial for MELAS and has a cleared IND for a Phase 2a trial in Leigh syndrome spectrum, with plans for a Phase 2 trial in pediatric MASH.
Average Trading Volume: 28,036
Technical Sentiment Signal: Buy
Current Market Cap: C$38.36M
For detailed information about TTI stock, go to TipRanks’ Stock Analysis page.